Statistics for Entrada Therapeutics, (id:6555 TRDA)

Valuation metrics

Market cap

667.69M

Enterprise value

243.96M

Trailing P/E (ttm)

12.40

Forward P/E

-5.67

PEG ratio

-5.67

Price/Sales (ttm)

3.10

Price/Book (mrq)

1.50

Enterprise Value/Revenue

1.13

Enterprise Value/EBITDA

3.98

Overview

Shares outstanding

37.41M

Float

18.44M

Shares short

1.66M

% Held by insiders

0.13%

% Held by institutions

0.81%

Average volume (10 days)

190.14K

Average volume (90 days)

Price summary

52-Week low

11.05

52-Week high

20.49

52-Week change

33.51%

Beta

-0.26

50-Day moving average

16.70

200-Day moving average

15.12

Dividends and splits

Forward annual dividend rate

Forward annual dividend yield

Trailing annual dividend rate

0.00%

Trailing annual dividend yield

0.00

5-Year annual dividend yield

Payout ratio

0.00

Dividend date

Ex-dividend date

Last split factor

2:1

Last split date

Financials

Fiscal year

Fiscal year ends

December 31th, 2023

Most recent quarter (mrq)

September 30th, 2024

Profitability

Profit margin

25.53%

Operating margin

-110.67%

Operational effectiveness

Return on assets

6.95%

Return on equity

16.42%

Income statement

Revenue (ttm)

6.07

Revenue per share (ttm)

6.07

Quarterly revenue growth (yoy)

Gross profit (ttm)

0.00

EBITDA

61.30M

Net income to common (ttm)

54.95M

Diluted EPS (ttm)

1.44

Quarterly earnings growth (yoy)

Balance sheet

Total cash (mrq)

449.34M

Total cash per share (mrq)

12.69

Total debt (mrq)

61.31M

Total Debt/Equity (mrq)

14.51

Current ratio (mrq)

659.10%

Book value per share (mrq)

11.93

Cash flow

Cash flow statement

-13,965,000.00

Levered free cash flow (LFCF)

-29,263,624.00